Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 16/20 | 0.63 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3113654 | 0.94 | KCNH2 (0.57) | KCNH2KCNQ1CACNA1C | |
| Fumaric Acid SCHEMBL3113645 | 0.94 | KCNH2 (0.57) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL703932 | 0.84 | KCNH2 (0.68) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL3100186 | 0.83 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| Hydrochloric Acid SCHEMBL3091416 | 0.83 | KCNH2 (0.63) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL13424693 | 0.81 | KCNH2 (0.55) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL13478974 | 0.79 | KCNH2 (0.55) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL13424849 | 0.79 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL3230092 | 0.79 | KCNH2 (0.67) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL3153796 | 0.79 | KCNH2 (0.73) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | claimed |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| WO-2008006648-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | KCNH2 2445/4885KCNQ1 1098/4885CACNA1C 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.